Use of testosterone replacement therapy to treat long-COVID-related hypogonadism
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can impair pituitary–gonadal axis and a higher prevalence of hypogonadism in post-coronavirus disease 2019 (COVID-19) patients compared with the general population has been highlighted. Here we report the first case of a patient affected w...
Main Authors: | Alessandro Amodeo, Luca Persani, Marco Bonomi, Biagio Cangiano |
---|---|
Format: | Article |
Language: | English |
Published: |
Bioscientifica
2024-04-01
|
Series: | Endocrinology, Diabetes & Metabolism Case Reports |
Online Access: | https://edm.bioscientifica.com/view/journals/edm/2024/1/EDM23-0097.xml |
Similar Items
-
The complications of male hypogonadism: is it just a matter of low testosterone?
by: Elisabetta Veronica Munari, et al.
Published: (2023-06-01) -
Genetic architecture of self-limited delayed puberty and congenital hypogonadotropic hypogonadism
by: Valeria Vezzoli, et al.
Published: (2023-01-01) -
FSH and bone: Comparison between males with central versus primary hypogonadism
by: Luca Giovanelli, et al.
Published: (2022-08-01) -
Editorial: Functional acquired hypogonadotropic hypogonadism in males
by: Biagio Cangiano, et al.
Published: (2024-01-01) -
Long-term testosterone replacement therapy reduces fatigue in men with hypogonadism
by: Maurício de Almeida Ferreira, et al.
Published: (2022-02-01)